Experience of application of activated glycyrrhizic acid.in vulvovaginitis, cervicitis, and genital papillomavirus infection

Objective: to evaluate the clinical efficacy of Epigen Intim, 0.1% spray, in patients with vulvovaginitis and/or cervicitis of nonspecific etiology and in those with genital papillomavirus infection (PVI). Subjects and methods. The investigation enrolled 60patients aged 18 to 56 years: Group 1 included 30patients with the clinical and laboratory signs of vulvovaginitis and/or cervicitis; Group 2 comprised 30 patients with PVI and HPV values of> 3 lg DNA copies per 100,000cells. All the patients were prescribed Epigen Intim, 0.1% spray, thrice daily intravaginally; it was additionally used topically in Group 2 patients (with the clinical manifestations of PVI). The treatment cycle for Groups 1 and 2 patients was 10 and 30 days, respectively. Results. After the treatment, there was a significant decrease in the detection rates for the subjective and objective signs of urogenital inflammatory diseases; normalization of leukocyte responses in the vagina (96.7%) and cervical canal (83.3%); reversion of the clinical manifestations of PVI (60.0%); elimination (20.0%) or a decrease in the HPV values to less than 3.0 lg HPV DNA copies per 100,000 cells (26.7%); and an improvement in the cytological examination of cervical scrapings (20.0%). Conclusion. Epigen Intim, 0.1% spray, showed a high efficiency profile in the treatment of urogenital infections and can be recommended as an anti-inflammatory, antiviral and immunostimulating agent for the treatment of vulvovaginitis, cervicitis, and genital PVI.

vulvovaginitis, cervicitis, papillomavirus infection, anogenital warts, human papillomaviruses, Epigen Intim, glycyrrhizic acid